CHINARES PHARMA (03320) announced the interim results of Jiang Zhong Pharmaceutical Co.,Ltd. for 2025. Total operating revenue reached approximately RMB 2.141 billion, representing a 5.79% decrease year-over-year. Net profit attributable to shareholders of the listed company was approximately RMB 522 million, marking a 5.8% increase compared to the same period last year. Basic earnings per share stood at RMB 0.82, with a cash dividend distribution of RMB 5 per 10 shares (including tax).
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.